Genmab — Marts 2017
-
det er vedtægter fra først på dagen
-
Ledende medarbejderes transaktioner oplyses ikke længere. Genmab henviser til et link. Mit normale link giver ikke mening https://oasm.finanstilsynet.dk/dk/soegeresultat.aspx?t=Genmab
-
96,000,000kr
-
så er der lidt til basserne!
-
jeg har altid været stor tilhænger af JVW, men jeg har altså lidt svært ved at se, hvordan man kan forsvare disse summer. De warrants er jo 30% af 2016s overskud,
-
80.000 aktier er jo i nærheden af 110 millioner kroner for ham
-
og vi snakker om en CEO med 200 ansatte under sig
-
Regarding the warrants:
-
-
- JvdW knows a lot more about the progressing of the different clinical studies then is public incl I/O. I believe he knows exactly what will happen in the comin 12 - 24 months and that is that there will be coming a flow of extremly significant data that will sky rocket the share price, therefore JvdW is certain that all Genmab shareholders will benefit significantly and that's why he believes the current warrant program is fair.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind